The Expressed Genome in Cardiovascular Diseases and Stroke: Refinement, Diagnosis, and Prediction: A Scientific Statement from the American Heart Association

Kiran Musunuru, Erik Ingelsson, Myriam Fornage, Peter Liu, Anne M. Murphy, L. Kristin Newby, Christopher Newton-Cheh, Marco V. Perez, Deepak Voora, Daniel Woo

Research output: Contribution to journalArticlepeer-review

Abstract

There have been major advances in our knowledge of the contribution of DNA sequence variations to cardiovascular disease and stroke. However, the inner workings of the body reflect the complex interplay of factors beyond the DNA sequence, including epigenetic modifications, RNA transcripts, proteins, and metabolites, which together can be considered the "expressed genome." The emergence of high-throughput technologies, including epigenomics, transcriptomics, proteomics, and metabolomics, is now making it possible to address the contributions of the expressed genome to cardiovascular disorders. This statement describes how the expressed genome can currently and, in the future, potentially be used to diagnose diseases and to predict who will develop diseases such as coronary artery disease, stroke, heart failure, and arrhythmias.

Original languageEnglish (US)
Article numbere000037
JournalCirculation: Cardiovascular Genetics
Volume10
Issue number4
DOIs
StatePublished - Aug 1 2017

Keywords

  • AHA Scientific Statements
  • DNA
  • cardiovascular diseases
  • epigenomics
  • genome
  • metabolomics
  • proteomics
  • stroke

ASJC Scopus subject areas

  • Genetics
  • Cardiology and Cardiovascular Medicine
  • Genetics(clinical)

Fingerprint Dive into the research topics of 'The Expressed Genome in Cardiovascular Diseases and Stroke: Refinement, Diagnosis, and Prediction: A Scientific Statement from the American Heart Association'. Together they form a unique fingerprint.

Cite this